… in the biology of RORγT agonists and their potential application in anticancer therapy. …
Lymphocytes treated with the RORγT agonist persisted as long-lived cells in the animals and …

… (62) In addition to Lycera, several pharmaceutical companies have begun to initiate
anticancer RORγ agonist projects (Table 1). Collectively, it can be concluded that synthetic RORγ …

… agonists that selectively activate RORγ to a greater extent than the endogenous agonist …
(B) Co-staining of IL-17A and RORγt shows partial overlap of RORγ and IL-17A expressing …

… Our results revealed that the RORγt agonist improved the efficacy of anti-PD-1. The RORγt
agonist … orphan receptor γ (RORγ) is a target for both anti-cancer and anti-inflammation drugs. …

… agonists of RORγt have been shown to increase the basal activity of RORγt enhancing T
H 17 cell proliferation. Here, we show that activation of RORγt using synthetic agonists drives …

… (RORγt) agonists are expected to provide a novel class of immune-activating anticancer drugs
… house well-optimized RORγt inverse agonists to potent RORγt agonists. We succeeded in …

… Selective enhancement (or activation) of the immune system by novel small molecules
may be a potential therapeutic approach for the treatment of cancer. RORγt (R etinoic Acid …

… in utilizing RORγ/RORγt antagonists and inverse agonists for additional immune-… in
treatment of castration-resistant prostate cancer [Citation18]. Alternatively, RORγ/RORγt agonists …

… -isopropanol derivatives as inverse agonist, sulfonamide derivatives as agonist or inverse
… in this invention have RORγt inhibitory action and are useful chemotherapeutic drugs for …

… RORγt agonist to evaluate the therapeutic potential and mechanism of action of targeting
RORγt … combined with anti-CTLA-4 antibodies increased anti-tumor therapeutic efficacy due to …